Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience

被引：0
|
作者：
Okunaka, Mashiro
Kotani, Daisuke
Demachi, Ken
Kawazoe, Akihito
Yoshino, Takayuki
Shitara, Kohei
机构：
[1] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[4] Natl Canc Ctr Hosp East, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
322
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer.
    Fukuda, Naoki
    Takahari, Daisuke
    Osumi, Hiroki
    Matsushima, Tomohiro
    Nakayama, Izuma
    Wakatsuki, Takeru
    Ogura, Mariko
    Ichimura, Takashi
    Ozaka, Masato
    Suenaga, Mitsukuni
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [42] A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
    Bando, Hideaki
    Shimodaira, Hideki
    Fujitani, Kazumasa
    Takashima, Atsuo
    Yamaguchi, Kensei
    Nakayama, Norisuke
    Takahashi, Takehiro
    Oki, Eiji
    Azuma, Mizutomo
    Nishina, Tomohiro
    Hironaka, Shuichi
    Komatsu, Yoshito
    Shitara, Kohei
    EUROPEAN JOURNAL OF CANCER, 2018, 91 : 86 - 91
  • [43] Randomized phase II trial of weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
    Hirata, K.
    Hamamoto, Y.
    Tsuchihashi, K.
    Kondoh, C.
    Yamazaki, K.
    Hironaka, S.
    Ando, M.
    Imamura, C. K.
    Yoshimura, K.
    Muro, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 323 - 323
  • [44] The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
    Zhang, Feng
    Wang, Yuyang
    Yang, Fangfang
    Zhang, Yuming
    Jiang, Man
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 535 - 546
  • [45] Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy
    Kakuta, Tomoyuki
    Yabusaki, Hiroshi
    Bamba, Takeo
    Aizawa, Masaki
    Nogami, Hitoshi
    Nomura, Tatsuya
    Matsuki, Atsushi
    Maruyama, Satoshi
    Takii, Yasumasa
    Nakagawa, Satoru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 684 - 693
  • [46] Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy
    Tomoyuki Kakuta
    Hiroshi Yabusaki
    Takeo Bamba
    Masaki Aizawa
    Hitoshi Nogami
    Tatsuya Nomura
    Atsushi Matsuki
    Satoshi Maruyama
    Yasumasa Takii
    Satoru Nakagawa
    International Journal of Clinical Oncology, 2021, 26 : 684 - 693
  • [47] Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer
    Aoki, Yu
    Sukawa, Yasutaka
    Kawasaki, Kenta
    Suzuki, Takeshi
    Hirata, Kenro
    Kasuga, Akiyoshi
    Iwasaki, Eisuke
    Hamamoto, Yasuo
    Takaishi, Hiromasa
    Kanai, Takanori
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
    Merz, Valeria
    Cavaliere, Alessandro
    Messina, Carlo
    Salati, Massimiliano
    Zecchetto, Camilla
    Casalino, Simona
    Milella, Michele
    Caffo, Orazio
    Melisi, Davide
    CANCERS, 2020, 12 (05)
  • [49] Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience
    Mashiro Okunaka
    Akihito Kawazoe
    Hitomi Nakamura
    Daisuke Kotani
    Saori Mishima
    Yasutoshi Kuboki
    Yoshiaki Nakamura
    Kohei Shitara
    Gastric Cancer, 2023, 26 : 1030 - 1039
  • [50] FOLFIRINOX and gemcitabine plus nab-paclitaxel as second-line or later chemotherapy and for locally advanced disease
    Maeda, Osamu
    Yokoyama, Yukihiro
    Ando, Yuichi
    ANNALS OF ONCOLOGY, 2016, 27
12345